150 related articles for article (PubMed ID: 29306309)
1. [Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin's lymphoma].
Fernández Cañabate E; Fernández-Cañabate S
Farm Hosp; 2018 Jan; 42(1):20-21. PubMed ID: 29306309
[TBL] [Abstract][Full Text] [Related]
2. Intraocular use of rituximab.
Kitzmann AS; Pulido JS; Mohney BG; Baratz KH; Grube T; Marler RJ; Donaldson MJ; O'Neill BP; Johnston PB; Johnson KM; Dixon LE; Salomao DR; Cameron JD
Eye (Lond); 2007 Dec; 21(12):1524-7. PubMed ID: 17464308
[TBL] [Abstract][Full Text] [Related]
3. Intraocular rituximab.
Singh AD; Peereboom DM
Eye (Lond); 2007 Dec; 21(12):1453-4. PubMed ID: 18159211
[No Abstract] [Full Text] [Related]
4. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.
Frenkel S; Hendler K; Siegal T; Shalom E; Pe'er J
Br J Ophthalmol; 2008 Mar; 92(3):383-8. PubMed ID: 18303160
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.
Rubenstein JL; Fridlyand J; Abrey L; Shen A; Karch J; Wang E; Issa S; Damon L; Prados M; McDermott M; O'Brien J; Haqq C; Shuman M
J Clin Oncol; 2007 Apr; 25(11):1350-6. PubMed ID: 17312328
[TBL] [Abstract][Full Text] [Related]
6. Management of non Hodgkin's intraocular lymphoma with intravitreal methotrexate.
de Smet MD
Bull Soc Belge Ophtalmol; 2001; (279):91-5. PubMed ID: 11344720
[TBL] [Abstract][Full Text] [Related]
7. Rituximab Faster Infusion for Patients With Non-Hodgkin's Lymphoma in the United States: Implications for Nursing Practice.
Dawson K
J Infus Nurs; 2015; 38 Suppl 6():S4-S10. PubMed ID: 26536411
[TBL] [Abstract][Full Text] [Related]
8. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.
Feugier P
Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779
[TBL] [Abstract][Full Text] [Related]
9. A possible coincidence of cytomegalovirus retinitis and intraocular lymphoma in a patient with systemic non-Hodgkin's lymphoma.
Svozílková P; Heissigerová J; Brichová M; Kalvodová B; Dvořák J; Ríhová E
Virol J; 2013 Jan; 10():18. PubMed ID: 23295015
[TBL] [Abstract][Full Text] [Related]
10. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma.
Larkin KL; Saboo US; Comer GM; Forooghian F; Mackensen F; Merrill P; Sen HN; Singh A; Essex RW; Lake S; Lim LL; Vasconcelos-Santos DV; Foster CS; Wilson DJ; Smith JR
Br J Ophthalmol; 2014 Jan; 98(1):99-103. PubMed ID: 24158837
[TBL] [Abstract][Full Text] [Related]
11. [Intravitreal chemotherapy for intraocular lymphoma].
Helbig H; Cerny T; de Smet MD
Ophthalmologe; 2003 Feb; 100(2):145-9. PubMed ID: 12589460
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse.
Klimova A; Heissigerova J; Rihova E; Brichova M; Pytlik R; Spicka I; Mrazova K; Karolova J; Svozilkova P
Br J Ophthalmol; 2018 Nov; 102(11):1579-1585. PubMed ID: 29378728
[TBL] [Abstract][Full Text] [Related]
14. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
Aurer I; Mitrović Z; Radman I; Kovacević-Metelko J; Nemet D; Serventi-Seiwerth R; Stern-Padovan R; Jakic-Razumović J; Nola M; Zupancić-Salek S; Sertić D; Labar B
Lijec Vjesn; 2004; 126(11-12):307-11. PubMed ID: 16082888
[TBL] [Abstract][Full Text] [Related]
15. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
16. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
King KM; Younes A
Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
Zinzani PL; Pellegrini C; Broccoli A; Gandolfi L; Stefoni V; Casadei B; Maglie R; Argnani L; Pileri S
Hematol Oncol; 2015 Sep; 33(3):141-6. PubMed ID: 24986783
[TBL] [Abstract][Full Text] [Related]
18. Peri-infusional adverse reactions to rituximab in patients with non-Hodgkin's lymphoma.
Arredondo-Garza T; Majluf-Cruz A; Vela-Ojeda J; Mariscal-Ramírez I; Solis-Anaya L; Lopez-Gutiérrez JR; Guadarrama CH; Rico-Curiel E; Armenta-San Sebastián JA; Castañeda-Hernández G
Arch Med Res; 2013 Oct; 44(7):549-54. PubMed ID: 24120421
[TBL] [Abstract][Full Text] [Related]
19. Systemic lupus erythematosus following rituximab treatment for non-Hodgkin lymphoma.
Soura E; Avgerinou G; Papoutsaki M; Stavropoulos P; Antoniou C
J Dtsch Dermatol Ges; 2016 Mar; 14(3):298-301. PubMed ID: 26788717
[No Abstract] [Full Text] [Related]
20. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma.
Ohguro N; Hashida N; Tano Y
Arch Ophthalmol; 2008 Jul; 126(7):1002-3. PubMed ID: 18625954
[No Abstract] [Full Text] [Related]
[Next] [New Search]
